biopharmaceutical

Financial Performance and Liquidity Altimmune reported a net loss of $27.4 million, or $0.27 per share, for the fourth quarter…

BrightSpring Health Services, Inc. (NASDAQ: BTSG), a provider of home and community-based health services, on Friday reported a sharp increase…

Executive Summary Viking Therapeutics remains entirely devoid of commercialized products and generates zero revenue, making its valuation highly dependent on…

Vertex Pharmaceuticals reported solid financial results for the fourth quarter of 2025, driven by continued demand for its cystic fibrosis…

Roivant Sciences (Nasdaq: ROIV) reported its financial results for the fiscal third quarter ended December 31, 2025, underscored by positive…

Roivant Sciences (Nasdaq: ROIV) on Friday reported its financial results for the fiscal third quarter ended December 31, 2025, revealing…